• Users Online: 2153
  • Print this page
  • Email this page
GUEST EDITORIAL
Year : 2014  |  Volume : 5  |  Issue : 1  |  Page : 1-3

Sorafenib and sunitinib: A dermatologist's perspective


Department of Dermatology, Command Hospital, Pune, India

Correspondence Address:
Vijendran Pragasam
Department of Dermatology, Command Hospital, Pune 411 040
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2229-5178.126017

Rights and Permissions

Sorafenib and sunitinib are inhibitors of tumor angiogenesis have recently generated curiosity regarding its role in cutaneous toxicities, which has severely affected the daily activities resulting in interruption or dose modification of therapy in renal cell carcinoma and hepatocellular carcinomas. We discuss the pathophysiology, adverse cutaneous effects and their grading, potential high risk factors, role of gene polymorphism, critical period of hand-foot skin reaction development and their management.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2314    
    Printed45    
    Emailed0    
    PDF Downloaded462    
    Comments [Add]    
    Cited by others 1    

Recommend this journal